KPV Peptide Research Guide: Alpha-MSH C-Terminal Tripeptide Mechanism, Literature, and Verification

Most peptides in a research library are built up from a signaling parent — longer, more elaborate, engineered for stability or receptor affinity. KPV runs the other way. It is what is left when you strip alpha-melanocyte-stimulating hormone (alpha-MSH) down to its final three amino acids and ask which part of the molecule still does the anti-inflammatory work. The striking answer from the literature is that this minimal C-terminal fragment — lysine, proline, valine — retains much of the parent hormone’s ability to quiet inflammatory signaling while shedding the sequence needed to bind melanocortin receptors and drive pigmentation. That dissociation of function from receptor is exactly what makes KPV an unusually clean tool compound. This guide surveys KPV at the molecular and preclinical level: what it is, how it engages intracellular signaling, what the primary literature actually reports, and how a research group should evaluate the material it sources. KPV is also topical: at the July 2026 PCAC meeting it was among the peptides recommended for addition to the 503A bulk drug substances list, which places renewed attention on how the compound is characterized and verified.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes.

Section 1 — Molecular Profile

KPV is the C-terminal tripeptide of alpha-MSH, corresponding to residues 11-13 of the parent 13-residue hormone. Its entire identity is captured in three letters — Lys-Pro-Val — which is both its name and its sequence.

KPV (Lysine-Proline-Valine)
– CAS number: 67727-97-3
– Molecular formula: C16H30N4O4
– Molecular weight: approximately 342.43 g/mol (342 Da)
– Length: 3 amino acids
– Sequence: H-Lys-Pro-Val-OH (alpha-MSH 11-13)
– Class: alpha-MSH-derived anti-inflammatory tripeptide; melanocortin-receptor-independent

Two structural facts drive everything downstream. First, KPV is very small — a tripeptide of only 342 Da — which is what allows it to be handled by cellular di- and tripeptide transport machinery and to be studied in oral-delivery model systems where larger peptides fail. Second, it deliberately lacks the core melanocortin pharmacophore (the His-Phe-Arg-Trp motif near the center of alpha-MSH) that is required for binding the melanocortin receptors. KPV therefore carries the anti-inflammatory “tail” of the hormone without the receptor-binding “head,” a separation of structure that becomes the central theme of its mechanism. A closely related compound, the tetrapeptide KdPT (Lys-D-Pro-Thr), is frequently studied alongside KPV as an analog probe.

Section 2 — Mechanism

KPV’s mechanism is best described at the intracellular signaling level, because the most-cited finding about the peptide is precisely that it does not require a cell-surface melanocortin receptor to act. In melanocortin-receptor-null cell lines, KPV retains anti-inflammatory activity, which is the experimental basis for calling its action receptor-independent.

The proposed route is transporter-mediated entry followed by intracellular pathway inhibition. KPV is a substrate for PepT1 (SLC15A1), a proton-coupled di/tripeptide transporter. In model systems of intestinal inflammation, PepT1 expression is upregulated in inflamed epithelium, so the same tissue that is inflamed becomes more efficient at importing the tripeptide — a feature that has made KPV a favored probe for studying targeted delivery into inflamed cells. Once inside the cell, KPV is reported to inhibit two convergent pro-inflammatory cascades: the NF-kB pathway and the MAP kinase (MAPK) pathway.

On the NF-kB arm, KPV is described as interfering with the nuclear translocation of the p65/p50 NF-kB subunits, reducing transcription of the downstream inflammatory gene program. The practical readout in cell models is suppression of pro-inflammatory cytokine output — TNF-alpha, IL-1beta, IL-6, and IL-8 among the commonly measured targets. Because this activity is preserved in cells lacking melanocortin receptors, the mechanism is understood as intracellular rather than GPCR-mediated. This is the mechanistic level at which everything in this article is framed: transporter uptake, inhibition of NF-kB and MAPK signaling, and the resulting change in cytokine transcription in cell and tissue models — not any systemic or clinical outcome.

Section 3 — Preclinical Research Data

The dissection of alpha-MSH into its active fragments is a well-characterized line of work, and KPV sits at the center of it. Foundational structure-activity studies established that the C-terminal tripeptide reproduces a substantial share of the parent hormone’s anti-inflammatory activity in vitro, and that the effect can be separated from the melanocortin pharmacophore responsible for pigmentation and receptor binding. This is the “dissociation” result that defines the compound: activity without receptor engagement.

A second, heavily cited body of work concerns transporter-mediated uptake in intestinal models. Investigators reported that KPV is taken up through PepT1 and, once internalized, reduces markers of intestinal inflammation in cell and rodent colitis models — the observation that inflamed colonic tissue upregulates PepT1 and thereby self-concentrates the peptide is a recurring theme. Related work has examined nanoparticle and oral-delivery formulations of KPV as a strategy for targeting gut inflammation, using the tripeptide’s small size and transporter compatibility as the enabling features.

Across these datasets the recurring research themes are minimalism and specificity: KPV is small enough to exploit peptide-transport machinery, and it inhibits convergent inflammatory pathways (NF-kB and MAPK) intracellularly rather than through a surface receptor. That combination is what makes it a clean experimental tool for isolating the anti-inflammatory tail of melanocortin signaling from the receptor-dependent effects of the full hormone.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for a KPV research library:

• Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology, 2008 (PMID 18242217).
• Kannengiesser K, Maaser C, Heidemann J, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases, 2008 (PMID 18240281).
• Getting SJ, et al. “Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.” Journal of Pharmacology and Experimental Therapeutics, 2003 (PMID 12750433).
• Xiao B, Xu Z, Viennois E, et al. “Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.” Molecular Therapy, 2017 (PMID 27852421).
• Brzoska T, Luger TA, Maaser C, et al. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo.” Endocrine Reviews, 2008.
• Luger TA, Brzoska T. “alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.” Annals of the Rheumatic Diseases, 2007 (PMID 17934088).

These references trace KPV from its receptor-independent anti-inflammatory pharmacology through transporter-mediated uptake to the delivery-formulation work that exploits its small size — the primary literature a research group needs to design and interpret in-vitro work.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, KPV is studied for a set of overlapping, model-system purposes:

• Receptor-independent anti-inflammatory reference: NF-kB reporter and cytokine-readout assays in melanocortin-receptor-null cell lines, using KPV to distinguish intracellular pathway inhibition from GPCR-mediated melanocortin signaling.
• PepT1 transport studies: using KPV as a model tripeptide substrate to probe SLC15A1-mediated uptake and its upregulation in inflamed epithelial models.
• Signaling-pathway work: dissecting KPV’s convergent inhibition of the NF-kB and MAPK cascades and the resulting changes in TNF-alpha, IL-1beta, IL-6, and IL-8 transcription in cultured cells.
• Delivery-formulation research: nanoparticle, hydrogel, and oral-delivery systems that exploit the tripeptide’s small size and transporter compatibility for targeted in-vitro and preclinical delivery studies.
• Structure-activity comparison: benchmarking KPV against the parent alpha-MSH and the KdPT analog to map which residues carry anti-inflammatory activity.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade KPV is supplied as a research chemical rather than a finished pharmaceutical preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage figure. A tripeptide is simple to synthesize but easy to contaminate with deletion sequences, unremoved protecting groups, or residual coupling reagents, all of which a chromatogram will reveal.
• LC-MS or MS identity confirmation of the ~342 Da target mass. Because KPV is so small, mass confirmation is the primary defense against a mislabeled or substituted short peptide.
• Endotoxin and heavy-metal testing for lyophilized material intended for cell-based work — especially relevant given KPV’s use in inflammation models, where endotoxin contamination would directly confound the readout.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, KPV is inexpensive to synthesize relative to long peptides, which means price competition is fierce and under-characterized material is common. For an anti-inflammatory research tool in particular, endotoxin data is not a formality: a “cheap” lot with no endotoxin figure can silently invalidate every NF-kB and cytokine measurement made with it. A low price attached to no verifiable COA is a red flag, not a bargain.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a tripeptide used specifically in inflammation research, orthogonal identity and endotoxin testing is not optional. It is the only way to confirm that a vial labeled as KPV contains the correct Lys-Pro-Val sequence at ~342 Da and carries a documented endotoxin figure — rather than a truncated sequence, a neighboring short peptide, or lyophilized material whose contamination would confound the very NF-kB and cytokine assays it is meant to support. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/kpv/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.

Further context: Interpret peptide purity and analytical testing.